GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » 5-Year EBITDA Growth Rate

EVAX (Evaxion Biotech AS) 5-Year EBITDA Growth Rate : 17.30% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS 5-Year EBITDA Growth Rate?

Evaxion Biotech AS's EBITDA per Share for the three months ended in Dec. 2024 was $-4.76.

During the past 3 years, the average EBITDA Per Share Growth Rate was 47.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Evaxion Biotech AS was 47.20% per year. The lowest was -63.10% per year. And the median was -5.65% per year.

Competitive Comparison of Evaxion Biotech AS's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Evaxion Biotech AS's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion Biotech AS's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's 5-Year EBITDA Growth Rate falls into.


;
;

Evaxion Biotech AS 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Evaxion Biotech AS  (NAS:EVAX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Evaxion Biotech AS 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
APRE DWTX GOVX ATHA SLXN TRAW SPRB INTI BRTX KAPA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, 2970
Website
https://www.evaxion.ai
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.